Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT00424528

Public ClinicalTrials.gov record NCT00424528. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Two-Week, Randomized, Modified-Blind, Double-Dummy, Parallel-Group Efficacy and Safety Study of Arformoterol Tartrate Inhalation Solution Twice-Daily, Tiotropium Once-Daily, and Arformoterol Tartrate Inhalation Solution Twice-Daily and Tiotropium Once Daily in Subjects With Chronic Obstructive Pulmonary Disease

Study identification

NCT ID: NCT00424528
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Enrollment: 235 participants

Conditions and interventions

Conditions

Interventions

Arformoterol Tartrate Inhalation Solution Drug
Tiotropium Drug
Arformoterol and Tiotropium Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 45 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 30, 2006
Primary completion: Sep 30, 2007
Completion: Sep 30, 2007
Last update posted: Jun 3, 2012

2006 – 2007

United States locations

U.S. sites: 28
U.S. states: 18
U.S. cities: 28

Facility	City	State	ZIP	Site status
Not listed	Jasper	Alabama	35501	—
Not listed	Tucson	Arizona	85715	—
Not listed	San Diego	California	92120	—
Not listed	Colorado Springs	Colorado	80909	—
Not listed	DeFuniak Springs	Florida	32435	—
Not listed	DeLand	Florida	32720	—
Not listed	Topeka	Kansas	66606	—
Not listed	Hazard	Kentucky	41701	—
Not listed	Madisonville	Kentucky	42431	—
Not listed	Marrero	Louisiana	70072	—
Not listed	Sunset	Louisiana	70584	—
Not listed	Ann Arbor	Michigan	48106	—
Not listed	Kalamazoo	Michigan	49007	—
Not listed	Saint Charles	Missouri	63301	—
Not listed	Charlotte	North Carolina	28207	—
Not listed	Cincinnati	Ohio	45242	—
Not listed	Columbus	Ohio	43215	—
Not listed	Eugene	Oregon	97404	—
Not listed	Medford	Oregon	97504	—
Not listed	Portland	Oregon	97213	—
Not listed	East Providence	Rhode Island	02914	—
Not listed	Lincoln	Rhode Island	02865	—
Not listed	Columbia	South Carolina	29201	—
Not listed	Simpsonville	South Carolina	29681	—
Not listed	Spartanburg	South Carolina	29303	—
Not listed	Knoxville	Tennessee	37920	—
Not listed	Tacoma	Washington	98405	—
Not listed	Morgantown	West Virginia	26505	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00424528, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 3, 2012 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00424528 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →